Studies Find Having COVID-19 May Protect Against Reinfection

Novel Coronavirus SARS-CoV-2 This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S. Virus particles are shown emerging from the surface of cells cultured in the lab. The spikes on the outer edge of the virus particles give coronaviruses their name, crown-like. Credit: NIAID-RML
FILE - This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a pa... FILE - This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to two new studies released on Tuesday, Dec. 22, 2020, people who have antibodies from infection with the coronavirus seem less likely to get a second infection for several months and maybe longer. (NIAID-RML via AP) MORE LESS
Start your day with TPM.
Sign up for the Morning Memo newsletter

Two new studies give encouraging evidence that having COVID-19 may offer some protection against future infections. Researchers found that people who made antibodies to the coronavirus were much less likely to test positive again for up to six months and maybe longer.

The results bode well for vaccines, which provoke the immune system to make antibodies — substances that attach to a virus and help it be eliminated.

Researchers found that people with antibodies from natural infections were “at much lower risk … on the order of the same kind of protection you’d get from an effective vaccine,” of getting the virus again, said Dr. Ned Sharpless, director of the U.S. National Cancer Institute.

“It’s very, very rare” to get reinfected, he said.

The institute’s study had nothing to do with cancer — many federal researchers have shifted to coronavirus work because of the pandemic.

Both studies used two types of tests. One is a blood test for antibodies, which can linger for many months after infection. The other type of test uses nasal or other samples to detect the virus itself or bits of it, suggesting current or recent infection.

One study, published Wednesday by the New England Journal of Medicine, involved more than 12,500 health workers at Oxford University Hospitals in the United Kingdom. Among the 1,265 who had coronavirus antibodies at the outset, only two had positive results on tests to detect active infection in the following six months and neither developed symptoms.

That contrasts with the 11,364 workers who initially did not have antibodies; 223 of them tested positive for infection in the roughly six months that followed.

The National Cancer Institute study involved more than 3 million people who had antibody tests from two private labs in the United States. Only 0.3% of those who initially had antibodies later tested positive for the coronavirus, compared with 3% of those who lacked such antibodies.

“It’s very gratifying” to see that the Oxford researchers saw the same risk reduction — 10 times less likely to have a second infection if antibodies were present, Sharpless said.

His institute’s report was posted on a website scientists use to share research and is under review at a major medical journal.

The findings are “not a surprise … but it’s really reassuring because it tells people that immunity to the virus is common,” said Joshua Wolf, an infectious disease specialist at St. Jude Children’s Research Hospital in Memphis who had no role in either study.

Antibodies themselves may not be giving the protection, they might just be a sign that other parts of the immune system, such as T cells, are able to fight off any new exposures to the virus, he said.

“We don’t know how long-lasting this immunity is,” Wolf added. Cases of people getting COVID-19 more than once have been confirmed, so “people still need to protect themselves and others by preventing reinfection.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Latest News

Notable Replies

  1. Good news at a nasty time. My hope has been that immunity to covid would be long term much like it is with polio. Then again we will be needing continuing vaccinations as ee do with the flu because covid will mutate over time as we have seen from the new strain out of Britain.
    I am well over 65 and I am looking forward to my two shots.
    Combine that with kicking trump out of office and we will be having a much better 2021 than this past year. I want no repeat of what we have been thru. I hooe somebody kept a copy of Obama’s epidemic playbook.

  2. I recall reading in multiple venues that the current vaccines are suspected (or confirmed?) to possibly offer immunity for as little as three months in some people. Yet that gets damn little play in the major media.

  3. It was exactly one year ago when I was afflicted with symptoms that were identical to many of the markers of COVID-19: loss of taste and smell, extreme lethargy, chills, 104ºF temperature, cough, diarrhea, pain all over. The fever waxed and waned as some vicious cycle of breaking, followed with a fever that roared back. There was no medical diagnosis for what I had as there were no tests.

    An antibody test would put my mind at ease. Reliable tests can be elusive, but hold some allure for me.

  4. “…up to six months and maybe longer.”

    Or maybe not.

  5. Avatar for noonm noonm says:

    I wouldn’t focus on the duration aspect yet (it will take years to fully determine how long infection or vaccination will protect). The important news in this study is that infection does confer some level of immunity, which has been presumed, but not confirmed, previously.

    That means our traditional approaches (public health measures, vaccinations, etc) can work if we use them effectively.

Continue the discussion at forums.talkingpointsmemo.com

30 more replies

Participants

Avatar for discobot Avatar for ajm Avatar for fess Avatar for zandru Avatar for steviedee111 Avatar for progress Avatar for Lacuna-Synecdoche Avatar for arrendis Avatar for bonvivant Avatar for gr Avatar for darrtown Avatar for docd Avatar for syvalley Avatar for bankerpup Avatar for patl Avatar for joriep Avatar for noonm Avatar for occamscoin Avatar for yellowbeard Avatar for txlawyer Avatar for rascal_crone Avatar for ClutchCargo

Continue Discussion
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Deputy Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: